Form 8-K · Current Report · Filed 2025-11-03
Metsera Responds to Pfizer Litigation Amid Acquisition Proposal
On November 3, 2025, Metsera, Inc. issued a statement in response to litigation filed by Pfizer Inc., asserting that Pfizer is attempting to lower the acquisition price through litigation. Metsera's Board of Directors is committed to standing firm on behalf of shareholders. The litigation could impact the proposed acquisition by Pfizer and the market price of Metsera's common stock.
- Filer
- MTSR MTSR
- Filed
- Accession
- 0001193125-25-262088
- CIK
- 0002040807
- Signal
- Medium impact
- Source
- Official filing on sec.gov ↗
Items reported
Other Events
Market reaction
Close before filing
$63.04
Next session
+16.1%
Since filing
+11.8%
Latest close
$70.50
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MTSR reporting the same item, with the next session's move:
Never miss another MTSR filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.